Distinct lung cancer subtypes associate to distinct drivers of tumor progression
Metrics: PDF 1331 views | HTML 2209 views | ?
Valeria Relli1, Marco Trerotola1,2, Emanuela Guerra1,2 and Saverio Alberti1,3
1Unit of Cancer Pathology, CeSI-MeT, University “G. d’Annunzio”, Chieti, Italy
2Department of Medical, Oral and Biotechnological Sciences, University “G. d’Annunzio”, Chieti, Italy
3Department of Biomedical Sciences, Dentistry, Morphological and Functional Imaging, University of Messina, Messina, Italy
Saverio Alberti, email: [email protected]
Keywords: non-small cell lung cancer; lung adenocarcinomas; lung squamous cell carcinomas; prognostic determinants; survival curves
Received: August 31, 2018 Accepted: September 26, 2018 Published: October 30, 2018
The main non–small-cell lung cancer (NSCLC) histopathological subtypes are lung adenocarcinomas (LUAD) and lung squamous cell carcinomas (LUSC). To identify candidate progression determinants of NSCLC subtypes, we explored the transcriptomic signatures of LUAD versus LUSC. We then investigated the prognostic impact of the identified tumor-associated determinants. This was done utilizing DNA microarray data from 2,437 NSCLC patients. An independent analysis of a case series of 994 NSCLC was conducted by next-generation sequencing, together with gene expression profiling from GEO (https://www.ncbi.nlm.nih.gov/geo/).
This work led us to identify 69 distinct tumor prognostic determinants, which impact on LUAD or LUSC clinical outcome. These included key drivers of tumor growth and cell cycle, transcription factors and metabolic determinants. Such disease determinants appeared vastly different in LUAD versus LUSC, and often had opposite impact on clinical outcome. These findings indicate that distinct tumor progression pathways are at work in the two NSCLC subtypes. Notably, most prognostic determinants would go inappropriately assessed or even undetected when globally investigating unselected NSCLC. Hence, differential consideration for NSCLC subtypes should be taken into account in current clinical evaluation procedures for lung cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.